Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyun J. | - |
dc.contributor.author | Tashkin, Donald P. | - |
dc.contributor.author | Gjertson, David W. | - |
dc.contributor.author | Brown, Matthew S. | - |
dc.contributor.author | Kleerup, Eric | - |
dc.contributor.author | Chong, Semin | - |
dc.contributor.author | Belperio, John A. | - |
dc.contributor.author | Roth, Michael D. | - |
dc.contributor.author | Abtin, Fereidoun | - |
dc.contributor.author | Elashoff, Robert | - |
dc.contributor.author | Tseng, Chi-Hong | - |
dc.contributor.author | Khanna, Dinesh | - |
dc.contributor.author | Goldin, Jonathan G. | - |
dc.date.accessioned | 2023-03-08T17:05:18Z | - |
dc.date.available | 2023-03-08T17:05:18Z | - |
dc.date.issued | 2016-07 | - |
dc.identifier.issn | 0003-4967 | - |
dc.identifier.issn | 1468-2060 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/64209 | - |
dc.description.abstract | Objectives The aim is to investigate whether the 12-month quantitative changes in high-resolution CT (HRCT) measures of interstitial lung disease (ILD) are different, and to understand how they change, in patients with scleroderma-related ILD who receive drug therapy versus placebo. Methods HRCT images were acquired at baseline and at 12 months in 83 participants in Scleroderma Lung Study I, a clinical trial comparing treatment with oral cyclophosphamide versus placebo. A computer-aided model was used to quantify the extent of fibrotic reticulation, ground glass and honeycomb patterns and quantitative ILD (QILD: sum of these patterns) in the whole lung and the lung zone (upper, middle or lower) of maximal disease involvement. Results Mean QILD score decreased by 3.9% in the cyclophosphamide group while increasing by 4.2% in the placebo group in the most severe zone (p=0.01) and decreased by 3.2% in the cyclophosphamide group while increasing by 2.2% in the placebo group in the whole lung (p=0.03). Transitional probabilities demonstrated greater changes from a fibrotic to either a ground glass or normal pattern in the cyclophosphamide group and the reverse in the placebo group. Conclusions Changes in quantitative HRCT measures of ILD provide a sensitive indication of disease progression and response to treatment. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BMJ PUBLISHING GROUP | - |
dc.title | Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment | - |
dc.type | Article | - |
dc.identifier.doi | 10.1136/annrheumdis-2015-208929 | - |
dc.identifier.bibliographicCitation | ANNALS OF THE RHEUMATIC DISEASES, v.75, no.7, pp 1367 - 1371 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000378055400029 | - |
dc.identifier.scopusid | 2-s2.0-84956672630 | - |
dc.citation.endPage | 1371 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1367 | - |
dc.citation.title | ANNALS OF THE RHEUMATIC DISEASES | - |
dc.citation.volume | 75 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordPlus | HIGH-RESOLUTION CT | - |
dc.subject.keywordPlus | SYSTEMIC-SCLEROSIS | - |
dc.subject.keywordPlus | CYCLOPHOSPHAMIDE | - |
dc.subject.keywordPlus | FIBROSIS | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordPlus | VARIABILITY | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordPlus | IMAGES | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.